Evidence map›Paper›PMID 41101946›Full record

ArticleStem cells translational medicine2025

iPSC-derived MSCs alleviate arthritis in collagen-induced arthritis mice by reducing synovial CD86h  iIL1βhi macrophage.

Zewen Wu, Yazhen Su, Jingxuan Li, Xinling Liu, Yang Liu, Li Zhao, LinXin Li, Chong Gao, Mingze Yao, Liyun Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zewen WuThird Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan 030032, China.ORCID 0000-0001-9124-4577
Yazhen SuThird Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan 030032, China.
Jingxuan LiThird Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan 030032, China.
Xinling LiuShanxi University of Chinese Medicine, Jinzhong 030619, China.
Yang LiuThird Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan 030032, China.
Li ZhaoShanxi Medical University, Taiyuan 030001, China.
LinXin LiThird Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan 030032, China.
Chong GaoPathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, United States.
Mingze YaoInstitutes of Biomedical Sciences, Shanxi Provincial Key Laboratory for Medical Molecular Cell Biology, Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education, Shanxi University, Taiyuan 030006, China.
Liyun ZhangThird Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan 030032, China.

Funding

Central Government Guidance on Local Science and Technology Development Fund YDZJSX2022B002Shanxi Bethune Hospital 2024AOXIANG02Shanxi Province Clinical Theranostics Technology Innovation Center for Immunologic and Rheumatic Diseases CXZX-202306Technology of Shanxi Province 2023XM058
6 · The paper itself

Abstract

backgroundJoint bone destruction in rheumatoid arthritis (RA) leads to poor prognosis, with current treatments mainly targeting inflammation and limited focus on bone damage. Mesenchymal stem cells (MSCs) offer anti-inflammatory and bone repair properties, but their clinical application is hindered by cellular heterogeneity. Induced pluripotent stem cell-derived mesenchymal stem cells (iMSCs) present a promising alternative due to their lower heterogeneity and replicative senescence, although their potential in RA treatment remains underexplored.

methodsiMSCs were injected intraarticularly in a collagen-induced arthritis (CIA) model. Treatment outcomes, including plantar swelling, joint score, histological and immunohistochemical staining, microCT imaging, and bone loss, were assessed. Single-cell RNA sequencing was employed to study iMSCs' effects on synovial macrophage subsets.

resultsIn vivo, iMSCs significantly reduced systemic inflammation and joint bone damage. Analysis of macrophage subpopulations revealed that iMSCs shifted macrophages from a pro-inflammatory CD86hiIL1βhi cluster to an anti-inflammatory CD86hiIL1βlo cluster, leading to reduced inflammation and bone resorption.

conclusionsiMSCs effectively alleviate inflammation and bone damage in CIA by modulating macrophage phenotypes, demonstrating potential for RA therapy.

Indexed as

Arthritis, ExperimentalB7-2 AntigenInduced Pluripotent Stem CellsMacrophagesMesenchymal Stem CellsMesenchymal Stem Cell TransplantationSynovial MembraneAnimalsArthritis, RheumatoidMaleMiceB7-2 Antigencellular therapyiMSCsiPSCsmacrophagerheumatoid arthritis

Identifiers

PMID41101946
PMCPMC12530881

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.